The Canadian Agency for Drugs and Technologies in Health (CADTH) is undertaking a project on less invasive treatment options for women who suffer from symptomatic uterine fibroids. Uterine fibroids are the most common benign pelvic tumours in women and can have a major impact on women’s health due to abnormal bleeding, pelvic or abdominal pain, and infertility. Surgical removal of the uterus (hysterectomy) is the conventional treatment for symptomatic uterine fibroids. While this can solve some of the problems, hysterectomy is also associated with a high risk of post-operative complications such as pain, and also results in infertility. Health care providers and patients are seeking other safe, effective, and less invasive alternatives to hysterectomy for these women.
This systematic review will address the effectiveness and safety of five uterine-preserving interventions available in Canada to alleviate fibroid-related health problems: uterine artery embolization, endometrial ablation, myomectomy, myolysis, and drug therapy. In addition, the economic literature will be reviewed to evaluate whether these interventions are cost-effective.
The project has two key components:
- Science report